Esophageal Cancer Pipeline Outlook, FDA Approvals, Clinical Trials and Companies 2024 (Updated)

DelveInsight, "Esophageal Cancer Pipeline Insight 2024" report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Esophageal Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Esophageal Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Esophageal Cancer Pipeline Report

*
DelveInsight's Esophageal Cancer pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Esophageal Cancer treatment.

*
The leading Esophageal Cancer Companies working in the market include BeiGene, AstraZeneca, CSPC ZhongQi Pharmaceutical Technology, Amgen, Jiangsu Hengrui Medicine, Oncolys Biopharma, Pfizer, Novartis, Luye Pharma, Eli Lilly and Company, ImmunoFrontier, Inc., Adaptimmune, Innovent Biologics (Suzhou) Co. Ltd., Genentech, Janssen Pharmaceuticals, Merck KGaA, Shenzhen Hornetcorn Biotechnology, Apexigen, Inc., Highlight Therapeutics, EMD Serono, HaiHe Biopharma, Lumicell, Jacobio Pharmaceuticals Co., Ltd., TESARO, Ascentage Pharma Group Inc., and others.

*
Promising Esophageal Cancer Therapies in the various stages of development include Panitumumab, Capecitabine, Oxaliplatin, Ramucirumab, Paclitaxel, Pertuzumab, trastuzumab and others.

*
May 2024:- Merck Sharp & Dohme LLC- A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Pembrolizumab (MK-3475) in Combination With Cisplatin and 5-Fluorouracil Versus Placebo in Combination With Cisplatin and 5-Fluorouracil as First-Line Treatment in Subjects With Advanced/Metastatic Esophageal Carcinoma (KEYNOTE-590). The purpose of this trial is to evaluate efficacy and safety of pembrolizumab plus standard of care (SOC) chemotherapy with cisplatin and 5-fluorouracil (5-FU) versus placebo plus SOC chemotherapy with cisplatin and 5-FU as first-line treatment in participants with locally advanced or metastatic esophageal carcinoma.

*
February 2024- Wuhan Ammunition Life-tech Co., Ltd- Methylation Detection of KCNA3 and OTOP2 Genes in Plasma for the Auxiliary Diagnosis of Esophageal Cancer/Precancerous Lesions: a Clinical Trial. Esophageal carcinoma is caused by abnormal hyperplasia of the squamous or glandular epithelium, the main pathological types are squamous cell carcinoma and adenocarcinoma. Globally, esophageal cancer has the seventh highest incidence and the sixth leading cause of cancer death. Statistics showed that in 2020, there were 604,000 new cases of esophageal cancer and 54.4 deaths.

*
January 2024:- Jiangsu HengRui Medicine Co., Ltd.- A Randomized, Open-Label, Active-Controlled, Multi-Center, Phase III Clinical Study of Anti-PD-1 Antibody SHR-1210 vs. Investigator's Choice of Chemotherapy in Subjects With Locally Advanced or Metastatic Esophageal Cancer. In this study, participants with advanced or metastatic squamous cell carcinoma of the esophagus that has progressed after first-line standard therapy will be randomized to receive either single agent SHR-1210 or the Investigator's choice of standard therapy with docetaxel or irinotecan. The primary study hypothesis is that treatment with SHR-1210 will prolong overall survival (OS) as compared to treatment with standard therapy.

Request a sample and discover the recent advances in Esophageal Cancer @ Esophageal Cancer Pipeline Outlook Report [https://www.delveinsight.com/sample-request/esophageal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Esophageal Cancer Overview

Esophageal cancer develops in the esophagus, which is the tube that connects the throat to the stomach. Tumors arise in the mucosa, which is the inner lining of the esophagus. There are two types of esophageal cancer, each with different risk factors: Adenocarcinoma -Cancers that start in gland cells at the bottom of the esophagus are called adenocarcinomas. This type of cancer is the most common esophageal cancer. It usually occurs closer to the stomach. Chronic acid reflux, gastroesophageal reflux disease (GERD), Barrett's esophagus and chronic heartburn can increase the risk of developing adenocarcinoma esophageal cancer.

Esophageal Cancer Emerging Drugs Profile

*
AN-0025: Adlai Nortye

AN0025 is a clinical stage, potential first-in-class EP4 antagonist designed to modulate tumor microenvironment. It blocks the PGE2-EP4 signaling pathway to inhibit PGE2-mediated immunosuppression in the tumor microenvironment. Currently, the drug is in Phase I stage of Clinical trial evaluation for the treatment of Esophageal Cancer.

*
Tucatinib: Seagen

Tucatinib (TUKYSA Registered ) is an oral medicine that is a tyrosine kinase inhibitor of the HER2 protein, a protein that contributes to cancer cell growth.HER2 is overexpressed in multiple cancers, including breast, colorectal, and gastric cancers. In preclinical in vitro studies, TUKYSA inhibited phosphorylation of HER2 and HER3, resulting in inhibition of downstream MAPK and AKT signaling and cell growth (proliferation), and showed anti-tumor activity in HER2-expressing tumor cells. In preclinical and clinical studies, TUKYSA inhibited the growth of HER2-expressing tumors. The combination of TUKYSA and the anti-HER2 antibody trastuzumab has also been shown to increase anti-tumor activity in vitro and in vivo compared to either medicine alone. Currently, the drug is in Phase II/III stage of Clinical trial evaluation for the treatment of Esophageal Cancer.

*
APX 005M: Apexigen

APX005M is a novel, humanized monoclonal antibody that stimulates the anti-tumor immune response. APX005M targets CD40, a co-stimulatory receptor that is essential for activating both innate and adaptive immune systems. Binding of APX005M to CD40 on antigen presenting cells (i.e., dendritic cells, monocytes and B-cells) initiates a multi-faceted immune response bringing multiple components of the immune system (e.g., T cells, macrophages) to work in concert against cancer. APX005M is currently in Phase 2 clinical development for the treatment of cancers such as pancreatic cancer, esophageal and gastroesophageal junction cancers, melanoma, non-small cell lung cancer, rectal cancer and sarcoma in various combinations with immunotherapy, chemotherapy, radiation therapy or a cancer vaccine.

Learn more about Esophageal Cancer in clinical trials @ Esophageal Cancer Drugs [https://www.delveinsight.com/sample-request/esophageal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Esophageal Cancer Therapeutics Assessment

There are approx. 80+ key Esophageal Cancer companies which are developing the therapies for Esophageal Cancer. The Esophageal Cancer companies which have their Esophageal Cancer drug candidates in the most advanced stage, i.e. phase II/III include, Seagen.

DelveInsight's Esophageal Cancer Pipeline Report covers around 100+ products under different phases of clinical development like

*
Late stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I) along with the details of

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

Discover more about Esophageal Cancer in development @ Esophageal Cancer Clinical Trials [https://www.delveinsight.com/sample-request/esophageal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Esophageal Cancer Companies

BeiGene, AstraZeneca, CSPC ZhongQi Pharmaceutical Technology, Amgen, Jiangsu Hengrui Medicine, Oncolys Biopharma, Pfizer, Novartis, Luye Pharma, Eli Lilly and Company, ImmunoFrontier, Inc., Adaptimmune, Innovent Biologics (Suzhou) Co. Ltd., Genentech, Janssen Pharmaceuticals, Merck KGaA, Shenzhen Hornetcorn Biotechnology, Apexigen, Inc., Highlight Therapeutics, EMD Serono, HaiHe Biopharma, Lumicell, Jacobio Pharmaceuticals Co., Ltd., TESARO, Ascentage Pharma Group Inc., and others.

Esophageal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

*
Intra-articular

*
Intraocular

*
Intrathecal

*
Intravenous

*
Ophthalmic

*
Oral

*
Parenteral

*
Subcutaneous

*
Topical

*
Transdermal

Esophageal Cancer Products have been categorized under various Molecule types such as

*
Oligonucleotide

*
Peptide

*
Small molecule

To know more about Esophageal Cancer, visit @ Esophageal Cancer Segmentation [https://www.delveinsight.com/sample-request/esophageal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Esophageal Cancer Pipeline Report

*
Coverage- Global

*
Esophageal Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination

*
Esophageal Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

*
Esophageal Cancer Companies- BeiGene, AstraZeneca, CSPC ZhongQi Pharmaceutical Technology, Amgen, Jiangsu Hengrui Medicine, Oncolys Biopharma, Pfizer, Novartis, Luye Pharma, Eli Lilly and Company, ImmunoFrontier, Inc., Adaptimmune, Innovent Biologics (Suzhou) Co. Ltd., Genentech, Janssen Pharmaceuticals, Merck KGaA, Shenzhen Hornetcorn Biotechnology, Apexigen, Inc., Highlight Therapeutics, EMD Serono, HaiHe Biopharma, Lumicell, Jacobio Pharmaceuticals Co., Ltd., TESARO, Ascentage Pharma Group Inc., and others.

*
Esophageal Cancer Therapies-Panitumumab, Capecitabine, Oxaliplatin, Ramucirumab, Paclitaxel, Pertuzumab, trastuzumab and others.

For further information on the Esophageal Cancer Pipeline Therapeutics, reach out @ Esophageal Cancer Products Development [https://www.delveinsight.com/sample-request/esophageal-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

*
Introduction

*
Executive Summary

*
Esophageal Cancer: Overview

*
Pipeline Therapeutics

*
Therapeutic Assessment

*
Esophageal Cancer- DelveInsight's Analytical Perspective

*
Late Stage Products (Pre-Registration)

*
Drug Name : Company Name

*
Drug profiles in the detailed report.....

*
Last Stage Products (Phase II/III)

*
Tucatinib: Seagen

*
Drug profiles in the detailed report.....

*
Mid Stage Products (Phase II)

*
APX 005M: Apexigen

*
Drug profiles in the detailed report.....

*
Preclinical and Discovery Stage Products

*
Drug Name : Company Name

*
Drug profiles in the detailed report.....

*
Inactive Products

*
Esophageal Cancer Key Companies

*
Esophageal Cancer Key Products

*
Esophageal Cancer - Unmet Needs

*
Esophageal Cancer - Market Drivers and Barriers

*
Esophageal Cancer - Future Perspectives and Conclusion

*
Esophageal Cancer Analyst Views

*
Esophageal Cancer Key Companies

*
Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=esophageal-cancer-pipeline-outlook-fda-approvals-clinical-trials-and-companies-2024-updated]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.